Evidence map›Paper›PMID 37140819›Full record

ArticleArchives of virology2023

Synthetic dibenzylideneketones as promising anti-herpes simplex virus type 1 agents.

Thalita Zago Oliveira, Dyenefer Pereira Fonseca, André Henrique Dos Santos, Thays Rosa da Silva, Danielle Lazarin-Bidóia, Zia Ud Din, Benedito Prado Dias Filho, Celso Vataru Nakamura, Edson Rodrigues-Filho, Tania Ueda-Nakamura

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of virology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 89% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Thalita Zago OliveiraDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Dyenefer Pereira FonsecaDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
André Henrique Dos SantosDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Thays Rosa da SilvaDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Danielle Lazarin-BidóiaDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Zia Ud DinLaboratory of Micromolecular Biochemistry of Microorganisms, Federal University of São Carlos, São Carlos, São Paulo, Brazil.
Benedito Prado Dias FilhoDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Celso Vataru NakamuraDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil.
Edson Rodrigues-FilhoLaboratory of Micromolecular Biochemistry of Microorganisms, Federal University of São Carlos, São Carlos, São Paulo, Brazil.
Tania Ueda-NakamuraDepartment of Basic Health Sciences, Laboratory of Technological Innovation in the Development of Drugs and Cosmetics, State University of Maringá, Avenida Colombo, 5790, Maringá, Paraná, 87020-900, Brazil. tunakamura@uem.br.ORCID http://orcid.org/0000-0001-5057-3518
Universidade Estadual de Maringá · BRUniversidade Federal de São Carlos · BR

Funding

CNPq 305903-2016
6 · The paper itself

Abstract

New antiviral agents for the treatment of herpes simplex virus type 1 (HSV-1) infection, which causes a highly prevalent and incurable disease, are needed. Here, we report for the first time the in vitro anti-HSV-1 activity of two dibenzylideneketone compounds: DBK1 and DBK2. DBK1 demonstrated virucidal activity, and high-resolution scanning electron microscopy showed that it caused morphological changes in the HSV-1 envelope. DBK2 was able to reduce HSV-1 plaque size in vitro. The DBKs are promising anti-HSV-1 candidates, as they exhibit low toxicity and exert an antiviral effect by acting at the early stages of HSV-1-host cell interaction.

Indexed as

Herpes SimplexHerpesvirus 1, HumanAntiviral AgentsHerpesvirus 2, HumanHumansAntiviral Agents

Identifiers

PMID37140819
OpenAlexW4368358802

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.